GLUE earnings date and last-quarter result: last quarter miss, P/E -12.79. Updated 2026-07-23.
Monte Rosa Therapeutics (GLUE) Research Hub
Monte Rosa Therapeutics (GLUE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 10.48 USD (-3.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.79, market cap 1.52B. This hub links to the full technical, earnings and options research available for GLUE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.48 USD (-3.32%) |
| 52-week range | 9.68 USD – 25.22 USD |
| Trend regime | Range |
| 14-day RSI | 56.7 (Bullish) |
| Trailing P/E | -12.79 |
| Market cap | 1.52B |
| Dividend yield | 0.00% |
Available research for GLUE
Covered Call on GLUE: how it works, illustrative setup around the real 10.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GLUE: how it works, illustrative setup around the real 10.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GLUE: how it works, illustrative setup around the real 10.48 USD price, max profit/loss, breakeven and when to use it. Educational.
GLUE technical analysis: range, last 10.48 USD, RSI 56.7, 52w range 9.68 USD–25.22 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GLUE in?
Monte Rosa Therapeutics (GLUE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GLUE in an uptrend or downtrend?
As of 2026-10-26, GLUE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GLUE's trailing P/E ratio?
GLUE's trailing P/E is -12.79, with a market cap of 1.52B. See the earnings research page for full valuation detail.